[8-K] CONMED Corporation Reports Material Event

Rhea-AI Filing Summary

CONMED Corporation announced its Board declared a quarterly cash dividend of $0.20 per share. The dividend was declared on August 7, 2025 and is payable on October 3, 2025 to shareholders of record as of September 15, 2025. This is a cash distribution to owners of the company and represents a direct return of capital to shareholders for the quarter.

The current 8-K contains only the dividend declaration and payment details; it does not disclose earnings, changes to dividend policy, or other financial metrics. Investors seeking additional context on the company’s payout history or cash position will need to consult recent periodic reports or investor presentations.

Positive

• Board declared a quarterly cash dividend of $0.20 per share, providing a clear cash return to shareholders
• Payment timing is specified: payable on October 3, 2025 to shareholders of record on September 15, 2025, giving investors certainty on receipt

Negative

• None.

Insights

Equity Analyst

TL;DR: CNMD declared a $0.20 quarterly cash dividend; routine shareholder distribution with no additional financial detail provided.

The filing documents a Board-approved quarterly cash dividend of $0.20 per share, payable Oct 3, 2025 with a record date of Sept 15, 2025. As presented, the disclosure is straightforward and purely operational: it notifies shareholders of timing and amount. The 8-K does not include contextual financial metrics, changes to dividend policy, or commentary on funding source, so material impact assessment requires cross-checking recent earnings, cash flow, and prior dividend history.

Corporate Governance Expert

TL;DR: Board action to declare a quarterly cash dividend; procedural disclosure aligns with governance norms but offers limited strategic insight.

The report records a Board decision to declare a quarterly cash dividend of $0.20 per share and specifies the payable and record dates. This is a routine corporate action announced via an 8-K to satisfy disclosure obligations. The filing does not indicate any change in dividend policy or board commentary on capital allocation, so governance implications are limited to demonstrating ongoing shareholder distributions.

FALSE000081695600008169562025-08-072025-08-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 7, 2025

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware			001-39218			16-0977505
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)

11311 Concept Blvd Largo, FL			33773
(Address of principal executive offices)			(Zip code)

(727) 392-6464

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.01 par value			CNMD			NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 8.01    Other Events

CONMED Corporation announced its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                    

Date: August 7, 2025			CONMED CORPORATION
			(Registrant)

By:			/s/ Todd W. Garner
Name:			Todd W. Garner
Title:			Executive Vice President, Finance & Chief Financial Officer

FAQ

What dividend did CONMED (CNMD) declare?

CONMED declared a $0.20 per share quarterly cash dividend.

When is the CNMD dividend payable and what is the record date?

The dividend is payable on October 3, 2025 to shareholders of record as of September 15, 2025.

Is there any information on CONMED's dividend policy or change in payout?

The 8-K only discloses the quarterly dividend amount and dates; it does not state any change to the company’s dividend policy.

Does the filing include earnings or cash flow details to support the dividend?

No. The filing contains only the dividend declaration and payment details and does not include earnings, cash flow, or funding-source information.

Where can investors find more context about CNMD's ability to pay dividends?

Investors should review CONMED’s recent periodic reports and investor presentations for financial metrics such as cash balances and operating cash flow.